|   | |
| Names | |
|---|---|
| Preferred IUPAC name 4-[4-(2H-1,3-Benzodioxol-5-yl)-5-(pyridin-2-yl)-1H-imidazol-2-yl]benzamide | |
| Identifiers | |
| 3D model (JSmol) | |
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
|  PubChem CID | |
| UNII | |
|  CompTox Dashboard (EPA) | |
| 
 | |
| 
 | |
| Properties | |
| C22H16N4O3 | |
| Molar mass | 384.395 g·mol−1 | 
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
SB-431542 is a drug candidate developed by GlaxoSmithKline (GSK) as an inhibitor of the activin receptor-like kinase (ALK) receptors, ALK5, ALK4 and ALK7. [1] However, it is not an inhibitor of anaplastic lymphoma kinase (which are commonly known as ALK inhibitors).
While SB-431542 has not proved directly useful for any clinical application, it is used for several applications in molecular biology. It suppresses the TGF-beta-induced proliferation of osteosarcoma cells in humans. [1] SB431542 can also be used in combination with LDN193189, CHIR99021 and DAPT to transform astrocytes into neurons. [2] It is also commonly used for immunological studies, for instance as a TGF-β inhibitor to facilitate the generation of dendritic cells from peripheral blood monocytes. [3]